- Home
- TRC vs TRDA Comparison
TRC vs TRDA Comparison
Compare TRC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- TRDA
- Stock Information
- Founded
- TRC 1843
- TRDA 2016
- Country
- TRC United States
- TRDA United States
- Employees
- TRC N/A
- TRDA N/A
- Industry
- TRC Real Estate
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- TRC Finance
- TRDA Health Care
- Exchange
- TRC Nasdaq
- TRDA Nasdaq
- Market Cap
- TRC 419.1M
- TRDA 502.9M
- IPO Year
- TRC N/A
- TRDA 2021
- Fundamental
- Price
- TRC $15.99
- TRDA $13.04
- Analyst Decision
- TRC
- TRDA Strong Buy
- Analyst Count
- TRC 0
- TRDA 3
- Target Price
- TRC N/A
- TRDA $25.67
- AVG Volume (30 Days)
- TRC 71.9K
- TRDA 98.3K
- Earning Date
- TRC 03-05-2025
- TRDA 03-12-2025
- Dividend Yield
- TRC N/A
- TRDA N/A
- EPS Growth
- TRC N/A
- TRDA N/A
- EPS
- TRC N/A
- TRDA 1.55
- Revenue
- TRC $40,118,000.00
- TRDA $215,232,000.00
- Revenue This Year
- TRC N/A
- TRDA $47.45
- Revenue Next Year
- TRC $16.57
- TRDA N/A
- P/E Ratio
- TRC N/A
- TRDA $8.41
- Revenue Growth
- TRC N/A
- TRDA 146.92
- 52 Week Low
- TRC $14.71
- TRDA $11.35
- 52 Week High
- TRC $19.82
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- TRC 50.32
- TRDA 43.00
- Support Level
- TRC $15.70
- TRDA $12.01
- Resistance Level
- TRC $16.54
- TRDA $13.62
- Average True Range (ATR)
- TRC 0.38
- TRDA 0.67
- MACD
- TRC -0.03
- TRDA 0.16
- Stochastic Oscillator
- TRC 59.73
- TRDA 45.58
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely commercial/industrial real estate development, resort/residential real estate development, mineral resources, farming, and ranch operations.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.